Log in


Abstract applications must be submitted using the online Abstract Application Portal. All users will need to enter their email and create a password specifically for this portal.  If you submitted an abstract previously, you must still create a new account. The portal is new each year. This log-in information is NOT the same as your username and password. 

Any accepted late breaking abstracts will be considered for in-person oral presentation only.

Note About Multiple Abstracts: If you have multiple abstracts to submit or if you already submitted an abstract during the regular abstract submission period, you may use the same email address to apply. 

The Abstract application deadline is Thursday, June 27, 2024 at 11:59pm Eastern Time (USA). 

Please refer to the information below to prepare for the submission of your abstract application online.  Please note: Only work that has not previously been published will be considered for acceptance.


Provide complete contact information for the author who will present the abstract at the Annual Meeting, including:
  • Full first and last name
  • Professional suffix (MD, PhD, etc.)
  • Institution
  • Address
  • City
  • State/province
  • Postal code
  • Country
  • Email address (will be used for all communications in regard to the abstract being submitted)
  • Phone number
  • Fax number


Type of Abstract Presentation Requested
Late breaking abstracts that are accepted will be eligible ONLY for oral presentation, in person at the meeting.  

Note: Late breaking abstracts will not be eligible for poster presentations, submitted to PBC for publication, included in the meeting program, or eligible for any of the prizes.

Abstract Title

List the complete title of the abstract in CAPITAL/UPPERCASE letters. 

Abstract Authors

  • List the full first and last names of all contributing authors by first name then last name.
  • The presenting author should be listed first.
  • Do not include degrees, titles, or appointments.
  • Do not use initials.

Institutional Affiliations

List the institutional affiliations of contributing authors. Please include superscript numbers indicating a link between a listed author and a listed institution.

Names of cities and countries with two words should be written in upper and lowercase letters (e.g. Czech Republic, South Africa, Los Angeles, St. Louis). For US authors, the city and state must be listed (e.g. Chicago, IL, Newark, NJ).

Abstract Text

Abstracts should adequately describe the objectives and results of the research. Provide the complete headings and text of your abstract according to the guidelines below. Applications that do not comply with the format below will not be reviewed or considered for presentation at the meeting. 

  1. Do not exceed 300 words in the text of the abstract; more than 300 words will not fit within the allotted text box in the online Abstract Application Form.
  2. The text of the abstract may not contain any tables, graphs, or lists.
  3. Periods should be used in numbers for decimal points, not commas (e.g. P=0.015).
  4. Numbers containing more than 3 digits should have a comma (e.g. 3,000).
  5. Abbreviations should be defined on first usage, then use of abbreviation alone is acceptable (e.g. Langerhans cell histiocytosis (LCH), then referred to as LCH in subsequent mention).
  6. The text of the abstract must contain these four headings/sections in one (1) continuous paragraph. Do not separate sections on new lines. The next heading should be listed and begin on the same line as the previous heading/section: 
    • Purpose - an introductory section indicating the purpose of the study
    • Methods - a brief description of pertinent experimental procedures
    • Results - a summary of the new unpublished data 
    • Conclusion - a statement of conclusion

Approval/status notifications will be sent on or about August 9, 2024.

About the Society

The Histiocyte Society is a nonprofit organization of more than 200 physicians and scientists from around the world committed to improving the lives of patients with histiocytic disorders by conducting clinical and laboratory research into the causes and treatment of this disease.

Copyright © 2023 Histiocyte Society

Phone: +1 856 589 6606 
Fax: +1 856 589 6614
332 N Broadway
Pitman, NJ 08071 USA

Powered by Wild Apricot Membership Software